{"DataElement":{"publicId":"7547065","version":"1","preferredName":"Multiple Myeloma RISS Stage","preferredDefinition":"A response used to determine the plasma cell myeloma stage defined according to the Revised International Staging System (RISS) criteria.","longName":"6711245v1.0:7547064v1.0","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"6711245","version":"1","preferredName":"Plasma Cell Myeloma RISS Stage","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)_A plasma cell myeloma stage defined according to the Revised International Staging System (RISS) criteria.","longName":"2647790v1.0:6711243v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2647790","version":"1","preferredName":"Myeloma","preferredDefinition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001) -- 2003","longName":"C3242","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Multiple Myeloma","conceptCode":"C3242","definition":"A bone marrow-based plasma cell neoplasm characterized by a serum monoclonal protein and skeletal destruction with osteolytic lesions, pathological fractures, bone pain, hypercalcemia, and anemia.  Clinical variants include non-secretory myeloma, smoldering myeloma, indolent myeloma, and plasma cell leukemia. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"32446690-9562-2995-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-06-06","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-06-06","modifiedBy":"ONEDATA","dateModified":"2007-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"6711243","version":"1","preferredName":"RISS Stage","preferredDefinition":"A plasma cell myeloma stage defined according to the Revised International Staging System (RISS) criteria.","longName":"C141392","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"RISS Stage","conceptCode":"C141392","definition":"A plasma cell myeloma stage defined according to the Revised International Staging System (RISS) criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8733A202-B4C8-6690-E053-F662850AD943","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-23","modifiedBy":"ONEDATA","dateModified":"2019-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8733A202-B4D9-6690-E053-F662850AD943","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-23","modifiedBy":"KUMMEROA","dateModified":"2020-01-30","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"7547064","version":"1","preferredName":"RISS Stage","preferredDefinition":"The extent of a cancer in the body. Staging is usually based on the size of the tumor, whether lymph nodes contain cancer, and whether the cancer has spread from the original site to other parts of the body.","longName":"7547064v1.0","context":"ECOG-ACRIN","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":null,"minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stage II","valueDescription":"RISS Stage II Plasma Cell Myeloma","ValueMeaning":{"publicId":"6711240","version":"1","preferredName":"RISS Stage II Plasma Cell Myeloma","longName":"6711240","preferredDefinition":"Not stage I or III. (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"RISS Stage II Multiple Myeloma","conceptCode":"C141395","definition":"Not stage I or III. (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"873366D0-5F07-11BD-E053-F662850A09FD","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-23","modifiedBy":"ONEDATA","dateModified":"2019-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8B592E4-842F-4EC2-E053-4EBD850ADFE9","beginDate":"2021-01-12","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-01-12","modifiedBy":"ONEDATA","dateModified":"2021-01-12","deletedIndicator":"No"},{"value":"Stage III","valueDescription":"RISS Stage III Plasma Cell Myeloma","ValueMeaning":{"publicId":"6711238","version":"1","preferredName":"RISS Stage III Plasma Cell Myeloma","longName":"6711238","preferredDefinition":"Serum beta-2-microglobulin 5.5 mg/L or more and high-risk cytogenetics and/or high LDH. High risk cytogenetics consist of one or more of the following: del17p, t(4;14), or t(14;16). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"RISS Stage III Multiple Myeloma","conceptCode":"C141396","definition":"Serum beta-2-microglobulin 5.5 mg/L or more and high-risk cytogenetics and/or high LDH. High risk cytogenetics consist of one or more of the following: del17p, t(4;14), or t(14;16). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"873366D0-5EE1-11BD-E053-F662850A09FD","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-23","modifiedBy":"ONEDATA","dateModified":"2019-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8B592E4-8419-4EC2-E053-4EBD850ADFE9","beginDate":"2021-01-12","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-01-12","modifiedBy":"ONEDATA","dateModified":"2021-01-12","deletedIndicator":"No"},{"value":"Stage I","valueDescription":"RISS Stage I Plasma Cell Myeloma","ValueMeaning":{"publicId":"6711242","version":"1","preferredName":"RISS Stage I Plasma Cell Myeloma","longName":"6711242","preferredDefinition":"Serum beta-2-microglobulin less than 3.5 mg/L and serum albumin 3.5 g/dL or more and no high-risk cytogenetics and normal LDH. High risk cytogenetics consist of one or more of the following: del17p, t(4;14), or t(14;16). (from AJCC 8th Ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"RISS Stage I Multiple Myeloma","conceptCode":"C141394","definition":"Serum beta-2-microglobulin less than 3.5 mg/L and serum albumin 3.5 g/dL or more and no high-risk cytogenetics and normal LDH. High risk cytogenetics consist of one or more of the following: del17p, t(4;14), or t(14;16). (from AJCC 8th Ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"873366D0-5F2D-11BD-E053-F662850A09FD","latestVersionIndicator":"Yes","beginDate":"2019-04-23","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2019-04-23","modifiedBy":"ONEDATA","dateModified":"2019-04-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"B8B592E4-8445-4EC2-E053-4EBD850ADFE9","beginDate":"2021-01-12","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-01-12","modifiedBy":"ONEDATA","dateModified":"2021-01-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2428501","version":"1","preferredName":"Stage","preferredDefinition":"The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"053C2A34-089B-693F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-11-11","endDate":null,"createdBy":"ALAIS","dateCreated":"2005-11-11","modifiedBy":"ONEDATA","dateModified":"2005-11-11","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8B592E4-83F6-4EC2-E053-4EBD850ADFE9","latestVersionIndicator":"Yes","beginDate":"2021-01-12","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-01-12","modifiedBy":"GARRIDOJ","dateModified":"2021-03-08","changeDescription":"Created for EAA181, 12 JAN 2021, JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"5936696","version":"1","longName":"Disease Assessment ","context":"ECOG-ACRIN"},{"publicId":"6013685","version":"1","longName":"Stratification Factor","context":"ECOG-ACRIN"},{"publicId":"10000277","version":"1","longName":"Eligibility","context":"ECOG-ACRIN"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Revised International Staging","type":"Preferred Question Text","description":"Revised International Staging System (R-ISS) Stage at Diagnosis/Study Entry","url":null,"context":"ECOG-ACRIN"}],"origin":"ECOG CRF:Eastern Cooperative Oncology Group Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"B8B592E4-8461-4EC2-E053-4EBD850ADFE9","latestVersionIndicator":"Yes","beginDate":"2021-01-12","endDate":null,"createdBy":"GARRIDOJ","dateCreated":"2021-01-12","modifiedBy":"GARRIDOJ","dateModified":"2021-03-08","changeDescription":"Created for EAA181, 12 JAN 2021, JG","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}